MD Anderson
MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib
The research will include preclinical and clinical studies of ROS1/NTRK inhibitor repotrectinib and MET inhibitor elzovantinib in several tumor types.
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
High tumor-specific mRNA levels were associated with increased risk of disease progression in 6,590 patient tumors across 15 cancer types.
Researchers will explore combination treatment strategies with Mirati's adagrasib that can help patients overcome both primary and acquired resistance.
Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer
The firm is evaluating its TCR-T cell therapy, engineered with the Sleeping Beauty transposon/transposase system, for solid tumors with certain hotspot mutations.Â